Mcdonald Capital Investors Inc. CA Has $121.22 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mcdonald Capital Investors Inc. CA lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 170,180 shares of the biopharmaceutical company’s stock after acquiring an additional 33,727 shares during the quarter. Regeneron Pharmaceuticals accounts for about 7.6% of Mcdonald Capital Investors Inc. CA’s holdings, making the stock its 6th biggest holding. Mcdonald Capital Investors Inc. CA’s holdings in Regeneron Pharmaceuticals were worth $121,224,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in REGN. Howe & Rusling Inc. increased its stake in shares of Regeneron Pharmaceuticals by 3.4% in the third quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $486,000 after buying an additional 15 shares during the period. Willner & Heller LLC increased its stake in shares of Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 15 shares during the period. OLD Second National Bank of Aurora increased its stake in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock worth $2,025,000 after buying an additional 15 shares during the period. Sigma Planning Corp increased its stake in shares of Regeneron Pharmaceuticals by 4.1% in the third quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company’s stock worth $430,000 after buying an additional 16 shares during the period. Finally, GLOBALT Investments LLC GA increased its stake in shares of Regeneron Pharmaceuticals by 1.5% in the third quarter. GLOBALT Investments LLC GA now owns 1,067 shares of the biopharmaceutical company’s stock worth $1,122,000 after buying an additional 16 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on REGN shares. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Piper Sandler reduced their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Finally, Bernstein Bank reduced their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Price Performance

REGN opened at $707.51 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a market capitalization of $77.35 billion, a P/E ratio of 18.48, a P/E/G ratio of 2.34 and a beta of 0.27. The company’s 50-day simple moving average is $696.12 and its two-hundred day simple moving average is $848.69. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the firm earned $11.86 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.